CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
申请人:Borriello Manuela
公开号:US20150087626A1
公开(公告)日:2015-03-26
There is described a novel group of cyclic amine derivative compounds, having an EP
4
receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases.
The present invention therefore relates to novel compounds which are selective antagonists of the EP
4
subtype of PGE
2
receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.
There is described a group of novel cyclic amine derivative compounds having an EP
4
receptor agonistic activity.
Specifically, the compounds according to the invention are provided with analgesic, antinflammatory, antiglaucoma activity, and also with anti-osteoporosis and antiulcerative activity.
The present invention therefore relates to novel cyclic amine derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis and osteoporosis.
The present invention provides a compound of the Formula II:
wherein X is:
R
1
is H, —CN, or F;
R
2
is H or methyl;
R
3
is H; and
R
4
is H, methyl, or ethyl; or
R
3
and R
4
joined together form a cyclopropyl ring;
or a pharmaceutically acceptable salt thereof.
There is described a group of novel cyclic amine derivative compounds having an EP4 receptor agonistic activity.
Specifically, the compounds according to the invention are provided with analgesic, antinflammatory, antiglaucoma activity, and also with anti-osteoporosis and antiulcerative activity.
The present invention therefore relates to novel cyclic amine derivative compounds, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as pain, glaucoma, ulcerative colitis and osteoporosis.